Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Savara Inc.

< Previous 1 2 3 4 Next >
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Proposed Public Offering
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Chief Medical Officer (CMO) Transition
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
Tickers SVRA
New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Participation in Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Participation in the Leerink Global Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
From Savara Inc.
Via Business Wire
Tickers SVRA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.